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Abstract. 
 
Mammalian vaults are ribonucleoprotein 
(RNP) complexes, composed of a small ribonucleic acid 
and three proteins of 100, 193, and 240 kD in size. The 
 
100-kD major vault protein (MVP) accounts for 
 
.
 
70% 
of the particle mass. We have identified the 193-kD 
vault protein by its interaction with the MVP in a yeast 
two-hybrid screen and confirmed its identity by peptide 
sequence analysis. Analysis of the protein sequence re-
 
vealed a region of 
 
z
 
350 amino acids that shares 28% 
identity with the catalytic domain of poly(ADP-ribose) 
polymerase (PARP). PARP is a nuclear protein that 
catalyzes the formation of ADP-ribose polymers in re-
sponse to DNA damage. The catalytic domain of p193 
was expressed and purified from bacterial extracts.
Like PARP, this domain is capable of catalyzing a 
poly(ADP-ribosyl)ation reaction; thus, the 193-kD pro-
tein is a new PARP. Purified vaults also contain the 
poly(ADP-ribosyl)ation activity, indicating that the as-
sembled particle retains enzymatic activity. Further-
more, we show that one substrate for this vault-associ-
ated PARP activity is the MVP. Immunofluorescence 
and biochemical data reveal that p193 protein is not en-
tirely associated with the vault particle, suggesting that 
it may interact with other protein(s). A portion of p193 
is nuclear and localizes to the mitotic spindle.
Key words: vaults • ribonucleoprotein particle • 
poly(ADP-ribose) polymerase • poly(ADP-ribose) • 
mitotic spindle
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AULTS
 
 have a mass of 13 MD, making them the
largest RNP complex found in the cytoplasm of
 
mammalian cells (Rome et al., 1991; Kickhoefer
et al., 1996). Initially identified in preparations of clathrin-
coated vesicles from rat liver, vaults were named for their
distinctive lobular morphology (Kedersha and Rome,
1986). They have since been identified in many other eu-
karyotes, including mice, bullfrogs, rabbits, 
 
Xenopus
 
, sea
urchins, and 
 
Dictyostelium
 
 (Kedersha et al., 1990; Hamill
and Suprenant, 1997). Vertebrate vaults are composed of
a small RNA and three proteins of 100 (formerly 104), 193
(formerly 192), and 240 (formerly 210) kD in size. The
vault-associated RNA (vRNA)
 
1
 
 has been cloned from sev-
eral species, including human, mouse, rat, and bullfrog
(Kickhoefer et al., 1993, 1998). vRNA length varies from
86 to 141 bases with some species containing multiple re-
lated RNAs. Mammalian vRNA sequences share 
 
z
 
80%
identity and can be folded into a similar predicted second-
ary structure. However, the vRNA is not a structural com-
ponent of the vault particle as it makes up 
 
,
 
5% of the
vault mass, and its degradation does not result in the gross
alteration of vault structure. The 100-kD subunit, termed
the major vault protein (MVP), constitutes 
 
.
 
70% of the
particle mass. Its cDNA has been cloned from human, rat,
 
Dictyostelium
 
, and electric ray, and its sequence is highly
conserved both at the gene and protein level (Vasu et al.,
1993; Kickhoefer and Rome, 1994; Scheffer et al., 1995;
Vasu and Rome, 1995; Herrmann et al., 1997). Vaults have
a unique barrel shape that consists of two halves, with each
half capable of opening into a flower-like structure with
eight petals surrounding a central ring. Each petal is
formed by 6 copies of MVP with 96 copies of MVP in the
intact vault particle (Kedersha et al., 1991).
Their ubiquitous distribution and highly conserved mor-
phology throughout eukaryotes suggests that vault func-
tion is essential, and that the structure of the particle must
be important for its function. Although the cellular role of
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rapid amplification of cDNA ends; TEP1, telomerase-associated protein
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the vault particle has remained elusive, several findings
support the notion that vaults may have a transport func-
tion. A reconstruction of the vault particle to 31 Å resolu-
tion has been completed recently (Kong et al., 1999). This
reconstruction showed little internal density, suggesting
that the purified vault particle is hollow on the inside, con-
sistent with a carrier and/or sequestration function. We
have quantitated the number of vaults in numerous cell
types and estimate that there are 10,000–100,000 vaults per
cell (Kickhoefer et al., 1998). Although the majority of
vaults are localized to the cytoplasm, some have consis-
tently been found in the nuclear fraction (Chugani et al.,
1993). This nuclear vault fraction is resistant to removal by
high salt and detergent washing, indicating that vault asso-
ciation with nuclei may be specific. Confocal microscopy
and immunofluorescence labeling indicate that the intact
particle is excluded from the nuclear lumen in mammalian
cells. In purified rat liver nuclei, vaults have been immu-
nolocalized to the nuclear membrane at or near nuclear
pore complexes (Chugani et al., 1993). Due to the similari-
ties in structure, mass, and symmetry, we have proposed
that vaults may be a nuclear pore complex plug and/or
transporter, or that they can interact with the nuclear pore
complex (Chugani et al., 1991). Additional evidence for
vaults as carriers comes from a study on the estrogen re-
ceptor in which increased levels of vaults were found in as-
sociation with estrogen receptors in nuclear extracts (Ab-
bondanza et al., 1998). In adult sea urchin coelomocytes,
which are cells responsible for cellular immunity, MVP is
localized to the nucleus and appears to be concentrated in
the nucleolus (Hamill and Suprenant, 1997). In 
 
Torpedo
 
electric ray, vaults are highly enriched in the electromotor
system where they are transported to the nerve terminal
(Herrmann et al., 1996, 1999). Vaults have been found to
be upregulated in some multidrug-resistant cancer cell
lines (Scheffer et al., 1995; Kickhoefer et al., 1998). One
mechanism for vault function in this process may be
through binding either directly or indirectly to drugs, or by
impeding the progress of the drugs to the nucleus or other
sites of drug action. These findings are consistent with the
idea of vault movement throughout the cytoplasm acting
as a carrier and potentially influencing the nucleus.
To complete our characterization of the vault compo-
nents, we have focused our attention on the higher molec-
ular weight vault proteins p193 and p240. We have re-
cently determined that the p240 vault protein is identical
to the mammalian telomerase-associated protein 1 (TEP1)
(Kickhoefer et al., 1999). TEP1 was first identified based
on its homology to the RNA-binding domain of 
 
Tetrahy-
mena
 
 p80 (Harrington et al., 1997; Nakayama et al., 1997).
The role of TEP1 in the telomerase complex has not yet
been defined. The sharing of the TEP1 protein by vaults
and telomerase suggests that TEP1 may play a common
role in some aspect of RNP structure, function, or assem-
bly. Here we describe the identification and characteriza-
tion of the 193-kD vault protein by its interaction with
MVP in a yeast two-hybrid screen and by peptide se-
quence analysis. The cDNA encodes a 1724 amino acid
(aa) sequence which contains a BRCA1 COOH terminus
(BRCT) domain, a region homologous to the catalytic do-
main of poly(ADP-ribose) polymerase (PARP), and a re-
gion similar to the inter–
 
a
 
-trypsin inhibitor protein. Ex-
 
pression of the putative p193 catalytic domain has allowed
assessment of this domain as a functional PARP. We also
show that p193 has poly(ADP-ribose) activity and that it
ADP-ribosylates the MVP in purified vaults.
 
Materials and Methods
 
Two-Hybrid Screening in Yeast
 
An NH
 
2
 
-terminal truncated MVP (bases 259–2754) was subcloned in two
steps into the EcoR1 and XbaI restriction sites of pEG202 (kindly pro-
vided by Dr. Roger Brent, Molecular Science Institute, Berkeley,
CA). The resultant plasmid, plex-MVP, and the reporter plasmid
pSH-18 were then transformed into yeast cells of the EGY48 strain
(Trp
 
2
 
Leu
 
2
 
His
 
2
 
Ura
 
2
 
, LacZ
 
2
 
). These cells were then transformed with a
HeLa cell acid fusion cDNA library in the pJG7-4 expression vector (con-
structed by J. Gyuris, Mitotix, Cambridge, MA, and kindly provided by
Dr. Roger Brent), and about 1 million transformants were plated onto
dropout media lacking Trp, His, and Ura containing glucose. Positive
clones were selected by replica plating onto dropout media lacking Trp,
His, Ura, and Leu containing galactose and X-gal. About 256 clones were
selected in the initial screen, but upon rescreening only 6 clones were able
to coactivate the lexA-responsive LEU2 and lacZ reporter genes of
EGY48 on galactose containing selection media. Putative interactor plas-
mids were rescued by transformation into KC8 cells. The six putative
clones were tested for the specificity of interaction by retransformation
into EGY48 along with the reporter plasmid pSH-18 and either the plex-
MVP or plex-bicoid as bait plasmids. Three clones specifically interacted
with plex-MVP only (the other three interacted with both baits suggesting
their interaction was nonspecific). The three interactor clones (8, 15, and
21) were sequenced and determined to be independent overlapping clones
of p193. All of the interactor clones contain the 3
 
9
 
 terminus of p193 begin-
ning at bases 4515 (clone 15), 4633 (clone 21), and 4791 (clone 8). In vitro
binding assays using glutathione 
 
S
 
-transferase (GST) fusion proteins and
in vitro translated MVP were carried out as described (Ausubel et al.,
1995).
 
Peptide Sequence Analysis
 
Vaults were purified from monkey liver as described previously (Keder-
sha and Rome, 1986; Kong et al., 1999). Purified vaults were fractionated
onto four 6% SDS polyacrylamide gels, stained with copper, and the ap-
propriate bands were excised. An estimated 26 pmol of the 193-kD vault
protein was sent to Dr. William S. Lane (Harvard Microchemistry Facility,
Cambridge, MA). Peptide sequences were determined on a Finnigan
TSQ-7000 Triple Quadrapole Mass Spectrometer. Previously, NH
 
2
 
-termi-
nal sequence analysis on p193 protein purified from bovine spleen vaults
and transferred to polyvinylidene difluoride (PVDF) membrane (Bio-Rad
Laboratories) was carried out by Dr. Audree Fowler (UCLA Protein Mi-
crosequencing Facility, University of California, Los Angeles School of
Medicine, Los Angeles, CA). Although the degenerate peptide sequence
was not useful for cloning, the sequence verified the NH
 
2
 
 terminus deter-
mined by 5
 
9 
 
rapid amplification of cDNA ends
 
 
 
(RACE).
 
Cloning of p193 Full-Length cDNA
 
To isolate the cDNA encoding p193, a human cDNA library (kindly pro-
vided by Dr. Owen Witte) was screened as described previously (Kick-
hoefer et al., 1993). A total of 500,000 recombinants were screened with a
randomly primed probe to the interactor clone 15 (EcoR1/XhoI, bases
4515–5490). 71 positive clones were identified. Restriction analysis deter-
mined the longest clone to be a 3-kb EcoR1 fragment (bases 2492–5490).
Reverse transcription followed by PCR was used to isolate bases 663–
2492. The first strand cDNA was synthesized using SuperScript II (Life
Technologies, Inc.) and random primers (16-mers, kindly provided by Dr.
Dohn Glitz, University of California, Los Angeles) from total HeLa cell
RNA. The following primers were used for reverse transcription PCR:
p193RB5 (5
 
9
 
-CCCCCGAATTCGTGGATGTCTTGCAGATATTTA-
GAGTT-3
 
9
 
), p193
 
1
 
2225 (5
 
9
 
-TTGGGAGATAGGCAGCAGACAAA-
CCGATGT-3
 
9
 
), p193RT5 (5
 
9
 
-CCTTATAAGCCCCTGGACATCAC-
ACCACCTCC-3
 
9
 
), and p193-RBD3 (5
 
9
 
-CCCGGATCCGGCCTTGGT-
GCTGCTGGAA-3
 
9
 
). The PCR products were digested with either
EcoRI (bases 1330–2492, amplified with p193RB5 and P193
 
1
 
2225) or
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Eco RV and BamHI (bases 663–1940, amplified with p193RT5 and
p193RBD3), and cloned into the corresponding sites in pBluescript SK
 
1
 
(Stratagene). The 5
 
9
 
 end of the cDNA clone (bases 1–663) was obtained
by 5
 
9 
 
RACE according to the manufacturer’s instructions (Life Technolo-
gies, Inc.) except poly(A)
 
1
 
 RNA from 293 cells was used in place of total
RNA. The gene-specific primers were GSP1 (5
 
9
 
-TCTGCCCAAAT-
CATCTCTACTAAA-3
 
9
 
) and GSP2 (5
 
9
 
-GAGTGCTTGAATTCAT-
GACTTCCTCC-3
 
9
 
). The amplified RACE product was digested with
EcoRV (base 663) and SalI (a site from the abridged universal anchor
primer) and was cloned into the corresponding sites in pBluescript SK
 
1
 
.
A complete p193 cDNA clone was assembled from various restriction
fragments. The NH
 
2
 
 terminus was tagged with VSVG (a 14 aa sequence,
YTDIEMNRLGK, from vesicular stomatitis virus glycoprotein) and sub-
cloned into the expression vector, pSVL (Amersham Pharmacia Biotech).
COS cells were transiently transfected with the lipid reagent DMRIE
(Life Technologies, Inc.) following the manufacturer’s guidelines.
 
Northern Analysis
 
A multiple tissue Northern blot containing 2 
 
m
 
g of poly(A)
 
1
 
 human RNA
was purchased from Origene and hybridized following their protocol with
a randomly primed p193 probe (bases 385–880). The blot was stripped
twice and hybridized first with a randomly primed MVP probe (bases
1–330) and then with a human 
 
b
 
-actin cDNA probe supplied by Origene.
 
Subcellular Fractionation and Analysis of p193
and MVP
 
Preparation of HeLa cell extracts (S100 and P100) and discontinuous su-
crose gradient fractionation of the P100 extracts were carried out as de-
scribed (Kickhoefer et al., 1998). The 100,000 
 
g
 
 pellet was resuspended by
dounce homogenization with a Teflon pestle. Both S100 and P100 extracts
and sucrose gradient fractions were resolved by SDS-PAGE and trans-
ferred to Hybond membrane (Amersham Pharmacia Biotech). The equiv-
alent of 1.2 
 
3
 
 10
 
6
 
 cells were represented in each lane of the S100 and P100
extracts. Equivalent aliquots of each of the sucrose gradient fractions were
represented. The membrane was incubated with affinity-purified anti-
p193 antibody (1:500), followed by an HRP-conjugated secondary anti-
body and visualized by ECL (Amersham).
 
Antibody Production
 
Two fragments of the p193-containing aa 408–611 (p193rbd) or 1471–1724
(p193int) were expressed in the pET expression system (Novagen) or as
GST fusion proteins (Amersham Pharmacia Biotech). The p193int (pET)
protein was purified on a His-bind column (Novagen) and injected into a
rabbit. Conversely, the p193rbd (pET) protein was present in the insolu-
ble fraction and was purified on an SDS-polyacrylamide gel; the appropri-
ate fragment was excised, minced, and injected into the same rabbit. A
p193 (408–611 or 1471–1724) containing GST fusion protein was coupled
to Affi-Gel 15 resin (Bio-Rad Laboratories) to make an affinity column.
Antiserum was initially purified on protein A as described (Sambrook et
al., 1989). After affinity purification on Affi-Gel 15 columns, the antibody
protein concentrations were too low to be measured by protein assay and
appropriate dilutions were determined by immunoblot analysis. Affinity-
purified Ig was used at 1:500 for immunoblot analysis.
 
Catalytic Activity Assays
 
The catalytic domain (aa 255–611) of p193 was amplified by PCR and in-
serted into the EcoR1 and XhoI sites of the pET28b expression vector.
His tagged p193cat (aa 255–611) protein was purified on a His-bind affin-
ity column. Poly(ADP-ribose) activity assays were carried out as de-
scribed previously (Simonin et al., 1993a,b; Smith et al., 1998). Reactions
contained 1 
 
m
 
g of purified p193 cat or 3 
 
m
 
g of purified rat liver vaults.
Vaults were purified from rat liver as described (Kedersha and Rome,
1986; Kong et al., 1999). Reactions were incubated at 25
 
8
 
C for 30 min in
assay buffer (0.1 ml) containing 50 mM Tris-HCl, pH 8.0, 4 mM MgCl
 
2
 
,
0.2 mM DTT, 1.3 
 
m
 
M [
 
32
 
P]NAD
 
1
 
 (4 
 
m
 
Ci; New England Nuclear), and 1
mM of unlabeled NAD
 
1
 
. Some assays contained the PARP inhibitor
3-aminobenzamide (3ABA) at 1 mM final concentration. Reactions were
stopped by the addition of TCA containing deoxycholate (as a carrier) to
a final concentration of 20% and 0.8 mg/ml, respectively. Precipitated pro-
teins were suspended in SDS loading buffer, and fractionated by SDS-
PAGE. Proteins were visualized by Coomassie blue stain and exposed to
PhosphorImager screens (Molecular Dynamics).
 
Immunofluorescence
 
HeLa cells or human foreskin fibroblasts were grown on coverslips until
 
z
 
50–70% confluent, then cells were fixed in 4% paraformaldehyde in
PHEM buffer (60 mM Pipes, 25 mM Hepes, 10 mM EGTA, 2 mM MgCl
 
2
 
,
pH 6.9), permeabilized and postfixed in methanol (Kedersha and Rome,
1990). The DNA damage experiments were carried out on human fore-
skin fibroblasts that were exposed to a UV Stratalinker 1800 (Stratagene)
using energy settings 50, 100, 150, and 200 
 
m
 
J. UV-treated cells were al-
lowed to recover for 24 h before immunostaining. Cells were stained with
DAPI (Sigma Chemical Co.) at 0.5 
 
m
 
g/ml. The following antibodies were
used for our immunofluorescence studies: affinity-purified anti-p193 poly-
clonal IgG was used at 1:100; affinity-purified anti–rat vault polyclonal
IgG was used at 1:100; a monoclonal anti-MVP (LRP56; kindly provided
by Dr. Rik Scheper, Academic Hospital, Vrije Universiteit, Amsterdam,
The Netherlands) (Scheper et al., 1993) IgG was used at 10 
 
m
 
g/ml; a mono-
clonal anti-p53 (BP53; Sigma Chemical Co.) was used at 1:200; a
polyclonal anti-PARP (Boehringer Mannheim) antibody was used at
1:2,000; and a monoclonal anti-tubulin (T4026; Sigma Chemical Co.) was
used at 1:200. Cells were incubated for 1 h in primary antibody followed
by a 30-min incubation with goat anti–rabbit Cy3 (1:250 dilution; Jackson
ImmunoResearch Laboratories), goat anti–mouse Cy3 (1:250 dilution;
Jackson ImmunoResearch Laboratories), or goat anti–mouse FITC (1:200
dilution; Jackson ImmunoResearch Laboratories). COS cells were trans-
fected with the VSVG-tagged p193 cDNA using the lipid reagent DMRIE
(Life Technologies, Inc.). Transiently transfected cells were fixed as de-
scribed above and immunostained with a monoclonal antiserum to the 14
aa VSVG epitope tag, anti-VSVG (P5D4; Sigma Chemical Co.) antiserum
at 1:500, followed by incubation with a goat anti–mouse Cy3 (1:250 dilu-
tion; Jackson ImmunoResearch Laboratories). Fixed cells were mounted
in polyvinyl alcohol–based mounting medium and viewed with a Nikon
FXA epifluorescence microscope.
 
Results
 
p193 Interacts with the MVP in a Yeast
Two-Hybrid Screen
 
To identify cellular proteins which interact with the MVP,
we pursued a yeast two-hybrid strategy (Fields and Song,
1989; Durfee et al., 1993; Gyuris et al., 1993). A cDNA se-
quence encoding the rat MVP (sequence data available
from EMBL/GenBank/DDBJ under accession no. U09870),
missing the NH
 
2
 
-terminal 67 aa, was inserted into the ex-
pression vector, pEG202. The resultant plasmid plex-MVP
encodes a hybrid protein containing the DNA-binding do-
main of lexA fused to MVP residues 68–885. We then
transformed the yeast strain EGY48 containing the lacZ
reporter (pSH18-34) and lex-MVP along with a galactose-
inducible HeLa acid fusion cDNA library. About 1 million
library transformants were screened, and 6 clones were
isolated that coactivated the lexA-responsive LEU2 and
lacZ reporter genes of EGY48. Three of the isolates inter-
acted specifically with lex-MVP in a yeast two-hybrid
retransformation assay where an irrelevant protein
(lexA-bicoid) was used as a negative control (Table I).
Nucleotide sequence analysis of the three isolates identi-
fied a previously determined nucleotide sequence of un-
known function (KIAA0177; sequence data available from
EMBL/GenBank/DDBJ under accession no. D79999).
The three overlapping clones encoded the COOH termi-
nus, beginning at aa 1471, 1510, and 1562, respectively
(Fig. 1). The region encoding aa 1562–1724 was designated
the MVP interaction domain (Fig. 1, IV), since it is
the smallest domain that we have tested that interacts
with MVP.
The results of the two-hybrid assay were consistent with
the results from an in vitro binding assay using a GST fu-
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sion protein. In this experiment, the p193 MVP interaction
domain (p193int) was expressed in 
 
Escherichia coli
 
 as a
GST fusion protein and was then bound to glutathi-
one beads. The beads were incubated with reticulocyte ly-
sate containing in vitro–translated 
 
35
 
S-labeled MVP, and
washed. Binding was assessed by fractionation on SDS-
PAGE, followed by PhosphorImager analysis (Fig. 2).
Concurrently, highly purified vaults from monkey liver
were fractionated by SDS-PAGE, stained, and the appro-
priate gel fragments (p193) were excised and sent to Wil-
liam S. Lane (Harvard Microchemistry Facility) for peptide
sequence analysis. One peptide sequence was obtained
(AALKNGETAEQLQK) and was determined to corre-
spond to nucleotides 639–680 of the KIAA0177 by a
TBLASTN search of the nonredundant nucleotide se-
quence database (Fig. 1). These results confirmed the
identity of the KIAA0177 sequence to be a truncated form
of the 193-kD vault protein. The 5
 
9
 
 end of the p193 cDNA
clone was obtained using 5
 
9
 
 RACE. The predicted NH
 
2
 
terminus was confirmed by earlier NH
 
2
 
-terminal aa se-
quence analysis of p193 protein purified from bovine
spleen vaults carried out by Audree Fowler (UCLA
Protein Microsequencing Facility). The bovine NH
 
2
 
-ter-
minal sequence MTV(L/G)IFAN(S/L)(T/P)F(Q/V)L veri-
fies the NH
 
2
 
 terminus of the p193 protein (Fig. 1). The se-
quence differences between the human and bovine p193
proteins probably represent species-specific variation. Al-
though the degenerate sequence was not useful for cDNA
cloning, it allows us to conclude that we have identified the
authentic NH
 
2
 
 terminus.
 
Structural Analysis of p193
 
The composite p193 cDNA is 5490 bases, with a short un-
translated 5
 
9
 
 end; the coding region encompasses bases
107–5281 and encodes a protein of 1724 aa. Fig. 1 shows
the 1724 aa sequence encoded by the p193 cDNA. The size
of the predicted protein was calculated to be 192.7 kD. A
PROSITE protein sequence analysis of the aa sequence
revealed several interesting features, thus allowing the se-
quence to be separated into four domains (Fig. 1, I–IV).
First, aa 1–94 were identified as a BRCT domain (Fig. 1,
I). BRCT domains were first identified in the BRCA1
gene and later were determined to define a superfamily of
cell cycle checkpoint DNA damage response proteins (Wu
et al., 1996; Bork et al., 1997; Callebaut and Mornon,
1997). The BRCT domain is thought to be important for
protein–protein interactions. Domain II is discussed be-
low. Domain III is formed by aa 616–706 and 877–919.
This domain shares 30 and 27% identity, respectively, with
the inter–
 
a
 
-trypsin inhibitor heavy chain–related protein,
a novel human plasma glycoprotein (Fig. 1, III) (Choi-Miura
et al., 1995). Domain IV is the MVP interacting domain
(discussed above; Fig. 1, IV).
The second domain, aa 209–563, shares 29% identity
 
Table I. Specificity of Interaction of p193int Domain Using 
Two-Hybrid Analysis
 
p193int
Bait proteins
lex-MVP lex-bicoid
 
8
 
1 2
 
15
 
1 2
 
21
 
1 2
 
1
 
 designates growth on selective media indicating both LEU2 and lacZ expression.
Figure 1. p193 is 1724 aa in length and can be di-
vided into four domains (I–IV). A PROSITE se-
quence motif search identified the NH2 terminus
(aa 1–94) as a BRCT domain (dark grey, I). aa
209–563 share 28% sequence identity with the
catalytic subunit of PARP (light grey, II). aa 616–
706 and 877–919 share 30 and 29% identity, re-
spectively, with the inter–a-trypsin inhibitor
heavy chain (broken boxes, III), although the sig-
nificance of this homology is not clear at present.
The COOH terminus (aa 1562–1724) defines the
region necessary for interaction with the MVP
(medium gray, IV). The nucleotide sequence
data are available from GenBank/EMBL/DDBJ
under accession no. AF158255.
Figure 2. In vitro binding as-
say of p193–MVP interaction.
In vitro–translated [35S]me-
thionine-labeled MVP was in-
cubated with GST fusion pro-
teins, GST only (lane 1), or
GST-p193int (lane 2) and glu-
tathione-agarose beads. After
extensive washing, proteins
extracted from the beads
were analyzed by SDS-
PAGE followed by Phosphor-
Imager analysis.
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with the catalytic subunit of PARP (PARP, sequence data
available from EMBL/GenBank/DDBJ under accession
no. G130781) (Fig. 3). PARP is a nuclear protein that can
be divided into three domains: the NH
 
2
 
-terminal DNA
binding domain (containing two zinc fingers), a central au-
tomodification domain, and a COOH-terminal catalytic
domain (for review see de Murcia et al., 1991). The cata-
lytic subunit binds to NAD
 
1
 
, hydrolyzes the nicotine moi-
ety, and polymerizes the ADP-ribose group in response to
DNA damage. Poly(ADP-ribose) is attached mainly to
PARP, but also to other substrates including histones H1
and H2B (Simonin et al., 1993b). A number of drugs have
been shown to bind to the active site of the catalytic sub-
unit, thus blocking NAD binding (including PD128763 and
3ABA; Ruf et al., 1996, 1998). The minimum region nec-
essary for PARP to retain catalytic activity is a 40-kD
fragment (aa 654–1014; Simonin et al., 1990). The crystal
structure of the catalytic fragment of PARP has been de-
termined (Ruf et al., 1996, 1998). Based on the crystal
structure, the residues that form the NAD binding pocket
are conserved between PARP and p193 (Fig. 3, shaded
residues). These data suggest that this region of the p193
will form a similar binding pocket, which could have cata-
lytic activity.
 
p193 Catalytic Activity
 
To determine whether p193 has PARP activity, the cata-
 
lytic domain of p193, aa 255–611, were expressed in 
 
E
 
.
 
coli
 
 as a His-tagged fusion protein and purified. An in
vitro PARP activity assay, which measures the addition
of radiolabeled ADP-ribose to protein acceptors with
[
 
32
 
P]NAD
 
1
 
 used as a substrate, was carried out. A Coo-
massie stain of the gel before exposure to a PhosphorIm-
ager screen shows that equal amounts of proteins were
used in all of the assays (Fig. 4, left panel). Like PARP, the
catalytic domain of p193 contains ADP-ribosylation activ-
ity, and it ADP-ribosylates itself (Fig. 4, right panel). This
activity is heat inactivatable (Fig. 4, right panel). The addi-
tion of unlabeled NAD
 
1
 
 (1 mM) decreased the level of
labeled ADP-ribose polymers added to p193 (255–611)
about threefold (Fig. 4, right panel). To confirm that the
labeling reaction with p193 was analogous to PARP-cata-
lyzed poly(ADP-ribosyl)ation, the PARP-specific inhibi-
tor 3ABA was included in a reaction. Modification of p193
(255–611) was decreased about twofold in the presence of
the inhibitor (Fig. 4, right panel). Furthermore, modified
p193 (255–611) reacted with a monoclonal anti–poly
(ADP-ribose) antibody (data not shown), consistent with
it carrying ADP-ribose polymers. These data indicate that
p193 (255–611) is a PARP.
Next, we wanted to investigate whether full-length en-
dogenous p193 within the vault particle would possess en-
zymatic activity. Highly purified vault particles were incu-
bated with [
 
32
 
P]NAD
 
1
 
 in the presence and absence of
inhibitor or unlabeled NAD
 
1
 
. The most prominently
Figure 3. Alignment of p193 and PARP catalytic
domains. Colons indicate conserved aa. Periods
indicate semi-conserved aa. Highlighted aa form
the binding pocket of the catalytic domain in the
crystal structure of the catalytic fragment of PARP
(Ruf et al., 1996, 1998).
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modified protein in purified vaults was the MVP. How-
ever, there was some labeling in the vicinity of the p193
and a high molecular weight smear was also detected (Fig.
5). Modification of all of these products was competed for
by the addition of unlabeled NAD
 
1
 
 and partially com-
peted by the addition of the inhibitor 3ABA. These data
 
indicate that full-length p193 is a PARP that is active in
the vault particle with at least one specific substrate, MVP.
 
Heterogenous Expression of p193 in Human Tissues
 
We determined the expression of p193 by Northern blot
analysis of human tissues, including brain, heart, kidney,
spleen, liver, and leukocytes (Fig. 6). In all tissues, except
brain, a 5.4-kb mRNA was readily detectable in 2 
 
m
 
g of
poly(A)
 
1
 
 RNA. The highest level of expression was seen
in kidney, with about equal levels detectable in spleen and
liver. The p193 mRNA tissue expression pattern is similar
to that of MVP; however, the level of expression in indi-
vidual tissues is variable, as there is a higher level of MVP
mRNA in spleen compared with liver (Fig. 6).
 
Subcellular Fractionation of p193
 
A polyclonal anti-p193 antibody was generated from bac-
terially expressed fragments of p193 (aa 408–611 and
1471–1724; see Materials and Methods). The anti-p193 an-
tibody recognizes a single protein species of 193 kD by im-
munoblot analysis (Fig. 7 A). To compare the subcellular
distribution of p193 with MVP, extracts from tissue culture
cells were isolated and fractionated on a discontinuous su-
crose gradient followed by immunoblot analysis (Fig. 7).
Vaults are cytoplasmic particles that typically pellet with
the microsomes at 100,000 
 
g
 
 (Kedersha and Rome, 1986).
Detergent-lysed HeLa cells were centrifuged at 20,000 
 
g
 
,
resulting in a nuclear (N) pellet. The supernatant was fur-
ther fractionated by centrifugation at 100,000 g and the
supernatant (S100) and pellet (P100) fractions were
analyzed by immunoblotting with anti-p193 antibody. In-
terestingly, unlike MVP, which primarily fractionates with
the P100, all of the fractions contained the p193 protein
(Fig. 7 A). We should note that the N fraction does not
Figure 4. The catalytic subunit of p193 is a PARP that ADP-
ribosylates itself. The catalytic domain of p193 (255–611) was ex-
pressed and purified from E. coli. In vitro assays containing p193
(255–611) were incubated in the presence of [32P]NAD1 and the
products separated by SDS-PAGE followed by Coomassie blue
staining (left panel) and by autoradiography (right panel). Reac-
tions contained 1 mg of p193 (255–611) and 1.3 mM [32P]NAD1.
Preincubation of p193 (255–611) at 658C for 10 min before the
addition of labeled NAD1 inactivated the activity (heat). Reac-
tions were supplemented with either 1 mM unlabeled NAD1
(cold chase) or with 1 mM 3ABA, the PARP inhibitor (inhibi-
tor).
Figure 5. In purified vaults, p193 is a PARP that ADP-ribosy-
lates itself and the MVP. Vaults (3 mg) purified from rat liver
were incubated in the presence of [32P]NAD1 (as indicated) and
the products separated by SDS-PAGE followed by Coomassie
blue staining (left panel), and by autoradiography (right panel).
Reactions were supplemented with either unlabeled NAD1
(Cold Chase) or with the PARP inhibitor 3ABA (Inhibitor). Ar-
rows indicate the specific ADP-ribosylated proteins. The bracket
indicates the smear of higher molecular weight ADP-ribosylated
products.
Figure 6. Tissue-specific expression patterns of p193 and MVP
are similar. A Northern blot (Origene) containing poly(A)1
RNA from human tissues was hybridized with either a 32P-
labeled probe specific for p193 (top), MVP (middle), or b-actin
(bottom) as described in Materials and Methods. The tissue
sources are indicated at the top of the blot.
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represent purified nuclei, and a certain portion of the cells
are in mitosis at any given time, so the amount of p193 de-
tected by immunoblotting may not be comparable to that
seen by immunofluorescence (see below). Further frac-
tionation of the P100 extract on a discontinuous sucrose
gradient revealed that the majority of p193 sedimented to
the 45/50% sucrose layer, coinciding with the pattern ob-
served for the MVP (Fig. 7 B). These results suggest that
all of the p193 protein in the P100 fraction is associated
with the vault particle. Immunoblot analysis of vaults puri-
fied from rat liver revealed that the p193 vault protein is
recognized by the anti-p193 antibody, further confirming
its association with vaults (Fig. 7 B). The shifted mobility
of p193 in vaults purified from rat liver is probably due to
species-specific differences.
Immunolocalization of p193
To determine the intracellular distribution of p193 in tis-
sue culture cells, we carried out immunostaining using af-
finity-purified anti-p193 antibody. Vaults have a punctate
cytoplasmic distribution (Fig. 8 and see Fig. 10; Kedersha
and Rome, 1990). They have also been localized to lamel-
lipodia and at the tips of actin filaments at or near adhe-
sion plaques (Kedersha and Rome, 1990). Immunofluores-
cence patterns observed for p193 have a similar punctate
cytoplasmic distribution. However, a variable number of
nuclear speckles are also detectable with anti-p193 anti-
body that is not seen with anti-vault antibody (Fig. 8 and see
Fig. 10). Double-immunofluorescence images revealed co-
incident staining of p193 and MVP in the cytoplasm, but
no coincident staining is detected in the nucleus. The lack
of completely coincident staining of p193 and MVP in the
cytoplasm is not surprising, as our fractionation studies
showed that not all of the p193 is associated with vaults.
Transfection of COS cells with a cDNA encoding p193
containing a VSVG epitope tag (VSVG-193) revealed that
the recombinant protein is distributed similarly to endoge-
nous p193 (Fig. 8 F). The p193 localization pattern is very
different from that seen for anti-PARP antiserum, which
showed a mostly nuclear staining pattern (Fig. 8 G). Inter-
estingly, in mitotic cells a portion of the p193 immunore-
activity localizes to the mitotic spindle (Fig. 9 A), like
b-tubulin (Fig. 9 B), with merged images depicting their
colocalization (Fig. 9, C and D). Vault staining of mitotic
cells is diffuse and punctate throughout the cytoplasm
(data not shown). Only a portion of the p193 is localized to
the mitotic spindle, as another exposure also shows the dif-
fuse punctate p193 staining in the cytoplasm (Fig. 9 D),
presumably representing the p193 in vaults. Next, we de-
termined whether the distribution of p193 or vaults varied
in response to DNA damage. Human foreskin fibroblasts
were UV irradiated (100 mJ), and the distribution of p53,
p193, and vaults was monitored by immunofluorescence
(Fig. 10). p53 is known to be activated in response to DNA
damage and is upregulated and localizes to the nucleus
(for review see Levine, 1997). No change in either the dis-
tribution of p193 or vaults was detectable in the UV-
treated cells (Fig. 10).
Discussion
Identification of the 193-kD vault protein completes the
molecular characterization of the repertoire of proteins
that form the basic vault particle. The identities of both
the 193- and 240-kD vault proteins have led to unexpected
but tantalizing findings. The determination that the 240-kD
protein is identical to the telomerase-associated protein,
TEP1, suggests that this protein may have a more general
role in RNP structure, function, or assembly (Kickhoefer
et al., 1999). The data presented here demonstrates that
the p193 provides vaults with an enzymatic activity. We
show that p193 is a PARP that ADP-ribosylates itself and
the major vault protein in purified vaults. Based on this
data we propose that p193 be named VPARP for vault
poly(ADP-ribose) polymerase. To date there are only
two other proteins that contain poly(ADP-ribosyl)ation
activity: PARP and tankyrase. PARP is a nuclear protein
that has been studied for nearly 20 yr (for reviews see de
Murcia et al., 1991; Jeggo, 1998). It is activated in re-
sponse to DNA damage, where it binds to DNA at single
or double-strand breaks and covalently attaches ADP-
ribose moieties derived from NAD1 to itself and other
nuclear proteins (de Murcia et al., 1991; Jeggo, 1998). PARP
Figure 7. p193 exists in cells associated with vaults and in other
subcellular fractions. Comparison of levels of p193 during bio-
chemical fractionation of HeLa cells. (A) Cellular protein frac-
tions, nuclear (N), supernatant S100 (S), and microsomal pellet
P100 (P) were generated from HeLa extracts and resolved by
SDS-PAGE (see Materials and Methods). Immunoblot analysis
was carried out using affinity-purified polyclonal antibody pre-
pared against recombinant p193 fragment. (B) The P100 fraction
was further fractionated on a discontinuous sucrose gradient (20/
30/40/45/50/60%), and the proteins from the gradient fractions
were resolved by SDS-PAGE. Immunoblot analysis was carried
out using either affinity-purified p193 polyclonal antibody (top)
or affinity-purified anti-vault polyclonal antibody (bottom). Su-
crose gradient fraction sources are indicated at the top. P100 rep-
resents the starting material, and the vault sample was purified
from rat liver (a lighter exposure of the detected MVP in purified
vaults is shown). Arrows indicate the positions of p193 and MVP.
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Figure 8. Subcellular localization of p193. Indirect immunofluorescence of endog-
enous p193 (A) and vaults (B) in HeLa cells reveals a punctate cytoplasmic stain-
ing pattern with some nuclear speckle staining with affinity-purified p193 anti-
body but not with the vault mAb (LRP56). By merging the images of A and B,
coincident staining is seen as yellow (C), revealing a partial overlap in the cyto-
plasm and highlighting the nuclear staining by p193. The nucleus is stained with
DAPI (D). Preimmune p193 antiserum reveals background staining (E). COS
cells transiently expressing VSVG-tagged p193 revealed that the recombinant
protein has an expression pattern similar to endogenous p193 (F). PARP is pre-
dominantly localized to the nucleus (G).
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has also been shown to be a target of caspases during apop-
tosis, where it is cleaved near the DNA binding domain
(Kaufmann et al., 1993; Lazebnik et al., 1994). Although
PARP knockout mice are viable, they are more sensitive
to gamma irradiation and treatment with the alkylating
agent N-methyl-N-nitrosourea (de Murcia et al., 1997).
Mice lacking PARP have recently been shown to be resis-
tant to pancreatic b-cell destruction and development of
type I diabetes induced by streptozocin (Burkart et al.,
1999; Masutani et al., 1999).
Recently, another PARP, tankyrase, was identified
through its ability to interact with TRF1 (Smith et al.,
1998). TRF1 is a mammalian telomeric protein that binds
to double-stranded telomere repeat containing DNA at
chromosome ends (for review see Smith and de Lange,
1997). Overexpression of TRF1 induces telomere shorten-
ing, whereas expression of a dominant negative TRF1 re-
sults in longer telomeres (van Steensel and de Lange,
1997). These data indicate that TRF1 is a negative regula-
tor of telomere length. TRF1 is not a component of telom-
erase; therefore, it must interact with other proteins that
mediate the interaction of telomerase with telomeres. One
such protein may be tankyrase. Tankyrase was shown to
ADP-ribosylate itself and TRF1, and this modification
abolishes the ability of TRF1 to bind to telomeric DNA
sequences in an in vitro gel shift assay. These results sug-
gest that poly(ADP-ribosyl)ation may negatively regulate
telomere length. Since the precise function of vaults is un-
known, it is difficult to assess the impact of poly(ADP-
ribosyl)ation on its function. However, it may enhance or
negate vault interaction with other proteins in the cell, or
it may allow for changes in vault conformation, i.e., open-
ing and closing of vaults.
A BRCT domain has been identified at the NH2 termi-
nus of VPARP. More than 50 distinct proteins have been
identified that contain a BRCT domain, and many of these
proteins have defined roles in the cellular response to
DNA damage (Wu et al., 1996; Bork et al., 1997; Callebaut
and Mornon, 1997). BRCT domains are thought to medi-
ate protein–protein interactions and are usually found at
either the NH2 or COOH termini of proteins. Some pro-
teins contain multiple copies of the BRCT domain. Inter-
estingly, PARP also contains a BRCT domain in the cen-
tral automodification domain upstream of the catalytic
domain (Bork et al., 1997). The BRCT domain in PARP is
separated from the catalytic domain by z145 aa, similar to
the distance that separates these two domains in VPARP
(115 aa). In some respects, multidrug resistance could be
Figure 9. A portion of the p193
colocalizes with b-tubulin to the mi-
totic spindle. Mitotic HeLa cells
were stained with anti-p193 (red, A)
and anti-b tubulin (green, B). A
merged image of A and B where co-
incident staining is yellow (C). An-
other coincident staining is shown
in D where the anti-p193 cytoplas-
mic staining is also evident (red
punctate staining).
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considered a response to DNA damage. Many chemother-
apeutic drugs are DNA-damaging agents (e.g., doxorubi-
cin and mitoxanthrone). The upregulation of vaults in
some types of multidrug-resistant cancers (Kickhoefer et
al., 1998; Scheffer et al., 1995), along with p193’s homology
to PARP, suggested that vaults may have a role in DNA
damage response. However, we have shown that when cel-
lular DNA is damaged by exposure to UV light sufficient
to activate p53, the distribution of vaults and VPARP re-
mains unchanged. In addition, we have determined that
VPARP activity is not activated by damaged DNA in ex-
tracts using an in vitro ADP-ribosylation assay (data not
shown). It seems reasonable to propose that like PARP,
VPARP activity will be activated by some as yet undeter-
mined signal. Other functional PARPs must exist, as
PARP-deficient mouse cells have recently been shown to
synthesize ADP-ribose polymers in response to the DNA-
damaging agent, N-methyl-nitro-nitrosoguanidine (Shieh
et al., 1998).
Northern blot analysis revealed a single VPARP mRNA
that is heterogenously expressed in human tissues, with
the highest amounts detectable in kidney. MVP showed a
Figure 10. Vaults and p193
are not relocalized in re-
sponse to DNA damage by
UV light. Human foreskin fi-
broblasts were either not
treated (A–C) or treated with
UV light (D–F). After 24 h,
cells were examined by in-
direct immunofluorescence
with a monoclonal p53 anti-
body (A and D), affinity-
purified p193 antibody (B
and E), or affinity-purified
vault antibody (C and F).
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similar pattern of expression, although levels varied de-
pending on the tissue being examined. Subcellular frac-
tionation of tissue culture cells revealed that z90% of the
MVP is present in the 100,000 g pellet (P100, crude vault
fraction) (Kickhoefer et al., 1998). However, only a por-
tion of VPARP, TEP1, and vRNA are associated with the
100,000 g vault particle fraction (Kickhoefer et al., 1999).
Factors governing vault particle formation, function, or as-
sembly have not been determined. It is possible that like
TEP1, VPARP may be a shared protein interacting with
other cellular proteins. TEP1 is associated with telom-
erase activity (Harrington et al., 1997; Nakayama et al.,
1997), and may have a more general role in RNP structure,
function, or assembly (Kickhoefer et al., 1999). The role of
vRNA in vault particle function has not yet been defined.
However, previous studies have demonstrated that the
vRNA is not a structural component of the vault particle
(Kedersha et al., 1991). Here we show that VPARP pro-
vides vaults with an enzymatic activity, and that this activ-
ity will likely be important in VPARP’s vault-independent
function. There are three potential nuclear localization sig-
nals in VPARP (aa 19 [PQQQKKK], aa 1237 [KRKHRK],
and aa 1244 [PFSKRF]) and a portion of the VPARP pro-
tein is localized to the nucleus by subcellular fractionation
and in a variable number of nuclear speckles by immuno-
fluorescence. VPARP is probably associated with other
cellular proteins and substrates that have not yet been
identified.
The localization of VPARP, but not of vaults, to the mi-
totic spindle is particularly intriguing, inasmuch as neither
vaults nor VPARP appears to associate with interphase
microtubules in HeLa cells. Vaults have been reported to
associate with microtubules in neurite extensions of differ-
entiated PC-12 cells (Herrmann et al., 1999), and sea ur-
chin vaults were originally discovered because of their
ability to copurify in vitro with egg microtubules through
several cycles of polymerization and depolymerization
(Hamill and Suprenant, 1997), although in adult sea urchin
coelomocytes, sea urchin vaults do not appear to associate
with microtubules by double immunofluorescence. It is
possible that a putative sea urchin VPARP could mediate
the vault association with egg microtubules in vitro, and
that the assembly and/or disassembly of egg microtubules
copurify selected microtubule-associated proteins specifi-
cally associated with the mitotic spindle. Examples of
other proteins that selectively associate with mitotic spin-
dle microtubules, but not interphase microtubules, include
human Eg5 and protein phosphatase g1 (Blangy et al.,
1995; Andreassen et al., 1998). The association of human
Eg5 with the mitotic spindle requires phosphorylation of a
specific threonine residue by p34cdc2. Protein phosphatase
g1 is an isoform of protein phosphatase 1 (PP1), a fam-
ily of serine/threonine phosphatases that has many impor-
tant regulatory functions in mammalian cells (Shenolikar,
1994). Recently it was recognized that the three isoforms
(a1, d1, and g1) are each localized to distinct sites in both
mitotic and interphase cells (Andreassen et al., 1998).
These findings suggest that these distinct localizations may
allow the various isoforms to control multiple cellular pro-
cesses. Precisely how VPARP is recruited to the mitotic
spindle is unknown. Posttranslational modifications to
VPARP such as phosphorylation, self-modification by
conjugation of poly(ADP-ribose) moieties, or interactions
with other protein(s) during mitosis are all candidate
mechanisms that could mediate interaction with the mi-
totic spindle. The key question that remains to be ad-
dressed in future studies is whether the spindle-associated
VPARP is enzymatically active, and if so, what is the func-
tion of such localized PARP activity. It is clear that vaults,
like Pandora’s box, contain surprises in addition to their
enigmatic contents.
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Note Added in Proof. While this manuscript was being reviewed, another
PARP (PARP2) was identified by Gilbert de Murcia and colleagues.
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